GHRP-2 is a synthetic growth hormone-releasing peptide that activates the ghrelin receptor. Small human experiments show two clear short-term effects: it can stimulate growth hormone secretion and increase food intake. Those findings are often expanded into claims about muscle gain, fat loss, recovery or anti-aging that the research has not established. GHRP-2 is not an FDA-approved treatment for those goals, and FDA has identified significant safety and quality concerns for compounded injectable and nasal products. This page separates measured effects from advertised outcomes.
What is GHRP-2?
GHRP-2, also called pralmorelin in some clinical literature, is a synthetic hexapeptide and agonist of the growth hormone secretagogue receptor, GHSR-1a. Ghrelin is the body's endogenous ligand for that receptor. Signaling through GHSR can influence pituitary growth hormone release, appetite, gastrointestinal function and neuroendocrine pathways.
This is a different route from the GHRH receptor used by sermorelin and CJC-1295. GHRP-2 is more closely related to GHRP-6 and ipamorelin, although selectivity, appetite effects and the amount of human evidence differ.
What human studies actually demonstrate
Growth hormone and other pituitary hormones
Controlled challenge studies in healthy adults show that GHRP-2 can produce an acute rise in growth hormone. A comparative human study by Arvat and colleagues also measured prolactin, ACTH and cortisol. GHRP-2 strongly stimulated GH and produced smaller but measurable increases in the other hormones.
That pattern matters. It means GHRP-2 is not a selective switch for growth hormone alone. The clinical implications of repeated ACTH, cortisol or prolactin changes have not been defined in a large long-term program.
Acute hormone-challenge studies are designed to characterize physiology. They do not demonstrate increases in strength, faster rehabilitation or improved quality of life.
Appetite and food intake
In a randomized, double-blind crossover experiment involving 19 lean and obese adults, GHRP-2 increased buffet food intake in a dose-dependent manner. Compared with placebo, the lower experimental infusion increased intake by about 10%, and the higher infusion by roughly 34%. Participants also reported greater appetite before the meal.
This is credible evidence of an acute appetite effect under controlled conditions. It is not evidence that unsupervised GHRP-2 use safely treats anorexia, improves athletic nutrition or produces desirable long-term body-composition changes. The study involved brief medically supervised infusions, not chronic real-world exposure.
| Research question | Evidence level | Responsible conclusion |
|---|---|---|
| Does GHRP-2 stimulate GH? | Small controlled human challenge studies | Yes, acutely |
| Can it increase food intake? | Randomized 19-person infusion study | Yes, during short experimental exposure |
| Does it selectively affect GH? | Comparative endocrine studies | No; ACTH, cortisol and prolactin can also change |
| Does it build muscle or reduce fat? | No robust long-term outcome trial | Unproven |
| Is chronic use safe? | Limited and heterogeneous human data | Unknown |
Diagnostic use is not general treatment approval
Some publications note that GHRP-2 has been used in Japan as a diagnostic stimulus for growth hormone secretion. A supervised diagnostic challenge has a defined protocol, medical setting and interpretive purpose. It does not validate products marketed elsewhere for body composition, anti-aging or routine appetite manipulation.
The same distinction applies to research in critically ill or cachectic patients. Findings in a narrow medical population cannot be converted into a wellness indication, especially when illness and concurrent treatment affect both benefit and harm.
FDA-identified safety and quality concerns
The FDA places GHRP-2 for injectable and nasal administration in category 2 of bulk substances that raise significant safety risks for 503B compounding. The agency cites possible immunogenicity from aggregation and peptide-related impurities, along with characterization challenges caused in part by an unnatural amino acid.
FDA also reports serious adverse events among people who received GHRP-2, including increased insulin requirements, infection, pancreatitis and deaths in critically ill study participants. The agency explicitly notes that causality has not been established. That caveat is important: these reports do not prove that GHRP-2 caused each event, but they rule out simplistic claims that human safety is settled.
Possible areas of clinical concern include:
- changes in glucose control or insulin requirements;
- appetite and unintended energy intake;
- cortisol and prolactin effects;
- immune reactions to a peptide or aggregates;
- nasal or injection-site complications;
- sterility and concentration errors in unapproved products.
No reliable consumer lab panel can make an inadequately studied product safe. Testing may detect some physiological changes, but it cannot confirm vial identity, predict an immune response or establish a favorable risk-benefit balance.
How GHRP-2 compares with related compounds
| Compound | Primary receptor pathway | Distinguishing evidence issue |
|---|---|---|
| GHRP-2 | GHSR-1a | Human appetite signal and non-GH hormone effects |
| GHRP-6 | GHSR-1a | Older human studies show GH plus ACTH/cortisol effects |
| Ipamorelin | GHSR-1a | Greater selectivity was shown mainly in animal pharmacology; phase 2 efficacy failed |
| MK-677 | GHSR-1a, non-peptide oral mimetic | Longer trials show more detailed metabolic and fluid-retention concerns |
| CJC-1295 | GHRH receptor | Long-acting DAC pharmacology and ambiguous commercial naming |
Calling one option "cleaner" does not establish safety. Each would need product-specific clinical evidence in the intended population.
Thailand and anti-doping checks
GHRP-2 being advertised online or by a clinic is not proof of Thai FDA approval. Use the official Thai FDA drug search to check the exact product and manufacturer, then ask a Thai-licensed pharmacist or physician to verify the registration and indication. A raw-material assay is not the same as approval of a sterile finished medicine.
For athletes, the answer is clearer. The 2026 WADA Prohibited List names growth hormone-releasing peptides, including GHRP-2, among growth hormone secretagogues prohibited at all times. Diagnostic or medical need requires formal anti-doping review; a prescription alone does not automatically create permission.
Common GHRP-2 mistakes
- Confusing an acute GH peak with better performance. A hormone response is not a functional endpoint.
- Ignoring the appetite signal. Increased intake may work against a body-composition goal.
- Calling GHRP-2 GH-selective. Human research found ACTH, cortisol and prolactin effects.
- Using diagnostic history as wellness validation. A supervised stimulation test is a different clinical use.
- Assuming a blend is studied. Combination products introduce new exposure and attribution questions.
- Downplaying critically ill patient reports. Uncertain causality still means safety cannot be declared.
Frequently asked questions
What does GHRP-2 do in human studies?
GHRP-2 acutely stimulates growth hormone and can increase appetite and food intake through the ghrelin receptor. These biomarker and short-term appetite effects do not establish long-term therapeutic benefit.
Is GHRP-2 an approved treatment for muscle gain or weight loss?
No. GHRP-2 is not FDA approved for muscle gain, fat loss, anti-aging, recovery or appetite treatment, and controlled long-term outcome data are lacking.
Does GHRP-2 affect hormones other than growth hormone?
It can. Human studies report smaller increases in prolactin, ACTH and cortisol as well as growth hormone, so describing it as a GH-only signal is inaccurate.
What to do with this evidence
If appetite, low weight, body composition or suspected hormone deficiency is the real concern, the useful next step is to identify its cause with a qualified clinician. Compare GHRP-2's short experimental findings with validated diagnostic methods and approved treatments, not with another catalog claim. The peptide evidence hub provides that broader framework, while the GHRP-6 guide explains the closest historical comparator.